Cytomegalovirus cultures during maintenance DHPG therapy for cytomegalovirus (CMV) retinitis in acquired immunodeficiency syndrome (AIDS).
Nine patients with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis on maintenance therapy with ganciclovir: 9(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) at high dose (30 mg/kg/week) or low dose (20 mg/kg/week) were tested every 1-2 weeks for CMV isolation from blood, saliva, and urine. Duration of therapy ranged from 1.5 to 12 months (average 5.3 months). During pretreatment and low-dose and high-dose maintenance therapy, CMV was isolated from 48/59 (81%), 90/211 (43%), and 40/290 (14%) of specimens, respectively. Three patients with progressive retinitis had viraemia more frequently than did six patients with stable retinitis, CMV being isolated from 29/47 (62%) and 17/121 (14%) of blood samples, respectively.
Jennens
I D
ID
Department of Medicine, Fairfield Infectious Diseases Hospital, Victoria, Australia.
Lucas
C R
CR
Sandland
A M
AM
Maclean
H
H
Hayes
K
K
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D000328:Adult; D003587:Cytomegalovirus / Q000187:drug effects / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy*; D006160:Guanosine Triphosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012173:Retinitis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D014766:Viremia / Q000150:complications / Q000188:drug therapy
C040342:9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate; D006160:Guanosine Triphosphate